CN113797267A - Compound aromatic essential oil and aromatic cotton tablet for dredging orifice - Google Patents

Compound aromatic essential oil and aromatic cotton tablet for dredging orifice Download PDF

Info

Publication number
CN113797267A
CN113797267A CN202111213239.3A CN202111213239A CN113797267A CN 113797267 A CN113797267 A CN 113797267A CN 202111213239 A CN202111213239 A CN 202111213239A CN 113797267 A CN113797267 A CN 113797267A
Authority
CN
China
Prior art keywords
essential oil
resuscitation
component
aromatic
compound aromatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111213239.3A
Other languages
Chinese (zh)
Inventor
邵征洋
詹璐
董晨霞
刘丽琴
叶杨
魏萌
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hangzhou Red Cross Hospital
Original Assignee
Hangzhou Red Cross Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Red Cross Hospital filed Critical Hangzhou Red Cross Hospital
Priority to CN202111213239.3A priority Critical patent/CN113797267A/en
Publication of CN113797267A publication Critical patent/CN113797267A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/26—Aristolochiaceae (Birthwort family), e.g. heartleaf
    • A61K36/268—Asarum (wild ginger)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/282—Artemisia, e.g. wormwood or sagebrush
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/284—Atractylodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/532—Agastache, e.g. giant hyssop
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention provides compound aromatic essential oil for resuscitation, which consists of an resuscitation component, a soothing component, an aromatic regulation component, a nerve regulation agent and sustained-release aroma-holding particles. On the basis of the components for dredging orifices, a soothing component, an aromatic regulation component, a nerve regulation agent and sustained-release fragrance-holding particles are added, and the composition is used as inhalation type essential oil, has the effects of dredging orifices, promoting local mucous membrane blood circulation, resisting bacteria and diminishing inflammation, and has a better treatment effect on seasonal allergic rhinitis.

Description

Compound aromatic essential oil and aromatic cotton tablet for dredging orifice
Technical Field
The invention relates to the technical field of essential oil, relates to essential oil with a medicinal effect, and particularly relates to aromatic resuscitation-inducing essential oil and an aromatic resuscitation-inducing cotton sheet.
Background
Under the influence of environment, people are increasingly affected by cold, nasal obstruction and even rhinitis, and the rhinitis belongs to the category of allergic rhinitis in traditional Chinese medicine. The deficient impairment of zang-fu organs and the affection of wind-cold are the pathogenesis of the disease and closely related to the lung, spleen and kidney. The body of the infant is tender, the functions of the viscera are immature, the infant is easy to be attacked by wind evil, and other pathogenic factors are mingled with the infant along with the change of seasons, so that the allergic rhinitis is caused. It has the characteristics of strong seasonal incidence, lingering and difficult healing and persistent repetition.
Chinese patent application with publication number CN105412247A discloses a nose-soothing essential oil, which comprises 10-25 parts by weight of magnolia flower essential oil, 10-20 parts by weight of radix angelicae essential oil and 10-20 parts by weight of base oil. Optionally one or two of herba Menthae essential oil, Eucalyptus essential oil, flos Lonicerae essential oil or fructus Xanthii essential oil.
Although the technical scheme adopts compound components, the technical scheme has a single formula, so that the technical scheme has a defect of lacking functionality, is more suitable for smearing and massaging local acupuncture points, is not suitable for being used as volatile compound essential oil, and has limited treatment efficacy.
Disclosure of Invention
The invention aims to solve the problems and provides the compound aromatic essential oil for resuscitation;
another object of the present invention is to provide an aromatic resuscitation-inducing cotton sheet.
In order to achieve the purpose, the invention adopts the following technical scheme:
a compound essential oil for resuscitation comprises resuscitation inducing component, soothing component, aroma regulating component, nerve regulating agent and sustained-release aroma-retaining particles.
In the compound aromatic essential oil for resuscitation, the components for resuscitation comprise dahurian angelica root essential oil, atractylodes rhizome essential oil, grassleaf sweelflag rhizome essential oil, patchouli essential oil, asarum herb essential oil and centipeda minima essential oil. Through compounding of various traditional Chinese medicine extracts, the traditional Chinese medicine composition has the effects of relieving exterior syndrome, dispelling wind, reducing swelling, expelling pus, resisting bacteria, diminishing inflammation, relieving cough, reducing sputum, dredging orifices, relieving pain and relieving upper respiratory infection symptoms.
In the compound aromatic essential oil for resuscitation, the soothing components comprise cinnamon essential oil and wormwood essential oil. The soothing component can help to generate a happy and exciting effect, relieve the mind and body, has the effect of warming and soothing, and is compounded with the resuscitation inducing component to make the essential oil components milder.
In the above compound aromatic essential oil for resuscitation, the aromatic regulation and control component comprises clove essential oil. Is used for regulating the fragrance of the essential oil, and has the effects of purifying air and further enhancing the antibacterial and anti-inflammatory effects.
In the compound aromatic essential oil for resuscitation, the nerve regulating agent comprises arbutin, theanine and caffeine. The nerve regulating agent with proper amount is added into the essential oil, can inhibit cyclic nucleotide phosphodiesterase, improve the AMP level and improve the blood viscosity, can alleviate the irritation of caffeine by matching arbutin, theanine and caffeine, mildly acts on the body, eliminates fatigue and simultaneously improves the capability of relieving physical and mental pressure, and has better treatment effect on allergic rhinitis.
In the compound aromatic essential oil for resuscitation, the slow-release aroma-holding particles comprise freeze-dried plant composite mineral crystal porous particles. The mineral salt contains silicate and metal elements, can continuously provide mineral components in essential oil, has antibacterial and anti-inflammatory effects, and has therapeutic effect on allergic rhinitis.
In the compound aromatic resuscitation-inducing essential oil, the preparation method of the freeze-dried plant composite mineral crystal porous particles comprises the following steps:
vacuum freeze drying pulverized plant, sieving to obtain plant lyophilized porous particles within 10 μm, mixing pulverized mineral crystal and plant lyophilized porous particles at a weight ratio of 1:1.3-1.8, grinding, and adding binder to obtain lyophilized plant composite mineral crystal porous particles.
Further, the plant for preparing the freeze-dried plant composite mineral crystal porous particles is one or a combination of more of angelica dahurica leaves, folium artemisiae argyi, mint leaves and centipeda minima.
Further, the mineral crystals used to make the freeze-dried plant composite mineral crystal porous particles are mineral salts.
Further, the binder may be methylcellulose, hydroxypropyl methylcellulose, or other cellulosic binders.
The amount of the binder is 1-3 wt% of the total amount of the mineral crystal and the plant lyophilized porous particles.
Preferably, the preparation method of the freeze-dried plant composite mineral crystal porous particles comprises the following steps:
removing impurities from plants, cleaning, crushing, performing vacuum freeze drying on the crushed plants at a temperature of between 50 ℃ below zero and 40 ℃ below zero under a vacuum degree of 8 to 13Pa by using a vacuum freeze dryer, sieving to obtain plant freeze-dried porous particles within 10 mu m, mixing and grinding crushed mineral crystals and the plant freeze-dried porous particles according to a weight ratio of 1:1.3 to 1.8, and adding a binder to prepare the freeze-dried plant composite mineral crystal porous particles with the particle size of 0.5 to 2 mm.
In the compound aromatic essential oil for resuscitation, the essential oil consists of 40 to 50 weight parts of resuscitation components, 5 to 10 weight parts of appeasing components, 0.5 to 1.5 weight parts of aromatic regulation and control components, 0.1 to 0.5 weight part of nerve regulation and control agents and 0.5 to 1.5 weight parts of slow-release aroma-holding particles;
the components for dredging orifices comprise angelica essential oil, rhizoma atractylodis essential oil, rhizoma acori graminei essential oil, patchouli essential oil, asarum essential oil and centipeda minima essential oil in a weight ratio of 3:3:3:1: 2;
the soothing component comprises cinnamon essential oil and wormwood essential oil in a weight ratio of 1: 2;
the aroma regulating component is clove essential oil;
the nerve regulating agent consists of arbutin, theanine and caffeine in a weight ratio of 2.5-3:2-3: 1;
the slow-release aroma-holding particles are freeze-dried plant composite mineral crystal porous particles.
Preferably, the essential oil consists of 45 parts by weight of resuscitation inducing component, 9 parts by weight of soothing component, 1 part by weight of fragrance regulating component, 0.5 part by weight of nerve regulating agent and 1 part by weight of sustained-release fragrance-holding particles.
The invention also provides an aromatic resuscitation-inducing cotton tablet, which comprises the cotton tablet containing the compound aromatic resuscitation-inducing essential oil.
In the compound essential oil for resuscitation with aromatics, the cotton sheet comprises a micropore liquid-locking layer and breathable cotton layers positioned on two sides of the micropore liquid-locking layer.
In the compound aromatic essential oil for resuscitation, the microporous liquid-retention layer is a honeycomb activated carbon sheet, an activated carbon fiber layer or an activated carbon sheet. The absorption of the essential oil can be enhanced, the attachment of the porous particles of the freeze-dried plant composite mineral crystal is facilitated, the essential oil is fully permeated into the micropore liquid locking layer, the adsorption capacity and the adsorption quantity of the essential oil are improved through the extremely large specific surface area of the active carbon, and the volatilization time of the essential oil is prolonged.
In the compound aromatic essential oil for resuscitation, the breathable surface layer is a non-woven cotton sheet.
Compared with the prior art, the invention has the advantages that:
on the basis of the components for dredging orifices, a soothing component, an aromatic regulation component, a nerve regulation agent and sustained-release fragrance-holding particles are added, and the composition is used as inhalation type essential oil, has the effects of dredging orifices, promoting local mucous membrane blood circulation, resisting bacteria and diminishing inflammation, and has a better treatment effect on seasonal allergic rhinitis.
Detailed Description
The present invention will be further illustrated with reference to the following examples.
Example 1
A compound essential oil for resuscitation comprises the following components,
components for dredging orifices: 63g of angelica essential oil, 63g of rhizoma atractylodis essential oil, 63g of rhizoma acori graminei essential oil, 63g of pogostemon cablin essential oil, 21g of asarum essential oil and 42g of centipeda minima essential oil;
soothing components: 21g of cinnamon essential oil and 42g of wormwood essential oil;
an aroma regulating component: 7g of clove essential oil;
a neuromodulatory agent: 1.5g of arbutin, 1.5g of theanine and 0.5g of caffeine;
sustained-release fragrance-holding particles: 7g of freeze-dried plant composite mineral crystal porous particles.
The preparation method of the freeze-dried plant composite mineral crystal porous particles comprises the following steps:
selecting folium artemisiae argyi, removing impurities, cleaning, crushing, performing vacuum freeze drying on the crushed folium artemisiae argyi at the temperature of between 50 ℃ below zero and 40 ℃ below zero under the vacuum degree of 8 to 13Pa by using a vacuum freeze dryer, sieving to obtain plant freeze-dried porous particles within 10 mu m, mixing and grinding crushed mineral crystals and the plant freeze-dried porous particles according to the weight ratio of 1:1.5, and adding methyl cellulose to prepare the freeze-dried plant composite mineral crystal porous particles with the particle size of 0.5 to 2 mm. The amount of methylcellulose is 3 wt% of the sum of the mineral crystals and the plant lyophilized porous particles.
Example 2
A compound essential oil for resuscitation comprises the following components,
components for dredging orifices: 56g of angelica essential oil, 56g of rhizoma atractylodis essential oil, 56g of rhizoma acori graminei essential oil, 56g of pogostemon cablin essential oil, 18.7g of asarum essential oil and 37.3g of centipeda minima essential oil;
soothing components: 18.7g of cinnamon essential oil and 37.3g of wormwood essential oil;
an aroma regulating component: 6.2g of clove essential oil;
a neuromodulatory agent: 1.3g of arbutin, 1.3g of theanine and 0.44g of caffeine;
sustained-release fragrance-holding particles: 6.5g of freeze-dried plant composite mineral crystal porous particles.
The preparation method of the freeze-dried plant composite mineral crystal porous particles comprises the following steps:
selecting mint leaves, removing impurities, cleaning, crushing, performing vacuum freeze drying on the crushed mint leaves at a temperature of between 50 ℃ below zero and 40 ℃ below zero under a vacuum degree of 8 to 13Pa by using a vacuum freeze dryer, sieving to obtain plant freeze-dried porous particles within 10 mu m, mixing and grinding crushed mineral crystals and the plant freeze-dried porous particles according to a weight ratio of 1:1.5, and adding methylcellulose to prepare the freeze-dried plant composite mineral crystal porous particles with the particle size of 0.5 to 2 mm. The amount of methylcellulose is 2 wt% of the total amount of mineral crystals and lyophilized plant porous particles.
Example 3
A fragrant orifice-opening cotton sheet is prepared by soaking a non-woven cotton sheet as a base material in the essential oil of example 1, and sufficiently absorbing the essential oil.
The cotton piece is circular with a diameter of 3 cm, and the amount of the essential oil used in example 1 is 10 pieces.
Example 4
As shown in fig. 1, an aromatic resuscitation-inducing cotton sheet is obtained by using an activated carbon sheet as a microporous liquid-blocking layer 2, immersing the microporous liquid-blocking layer 2 in essential oil of example 1 to sufficiently absorb the essential oil, and then bonding or sewing a fiber cotton sheet as an air-permeable cotton layer 3 to both sides of the microporous liquid-blocking layer 2.
The slow-release fragrance-holding particles in the essential oil are locked in the micropore liquid-locking layer 2, so that the slow-release effect of the essential oil can be improved, and the fragrance-holding time of the essential oil can be prolonged.
The cotton piece is circular with a diameter of 3 cm, and the amount of the essential oil used in example 1 is 7 pieces.
Comparative example 1
This comparative example is the same as example 4, except that the essential oil does not contain a neuromodulatory agent.
Comparative example 2
This comparative example is the same as example 4, except that the essential oil does not contain the sustained-release fragrance-retaining particles.
Comparative example 3
This comparative example is the same as example 4 except that the nerve-regulating agent of essential oil does not contain theanine and arbutin.
Comparative example 4
This comparative example is the same as example 3, except that the essential oil does not contain the sustained-release fragrance-retaining particles.
Application example 1
The cotton sheets of example 4, comparative example 1, comparative example 2 and comparative example 3 were placed in cotton sheet clips as test samples 1 to 4, 4 each, and a blank cotton sheet was placed in the cotton sheet clip as a blank sample.
And selecting 17 allergic rhinitis patients, respectively reducing the air-conditioning temperature of 1 ℃ in the same closed air-conditioning room every 20 minutes from 22 ℃, and respectively recording the temperature of nasal obstruction of each patient.
The 16 test samples and 1 blank sample were randomly distributed to 17 patients, and after being placed at the bedside for 2 weeks of continuous use, the 17 patients were arranged in the same air-conditioned room again, the air-conditioned temperature of 1 ℃ was reduced every 20 minutes from 22 ℃, and the temperature at which nasal congestion began to appear in each patient was recorded again.
The results are shown in the following table:
Figure BDA0003309642190000071
the result shows that the essential oil cotton tablet provided by the invention can improve the treatment effect on allergic rhinitis, improve the tolerance of rhinitis patients to temperature and greatly improve the effective rate.
Application example 2
The cotton sheets of example 3, example 4, comparative example 2 and comparative example 4 were placed in cotton sheet clips as test samples 5 to 8, respectively, and placed in parallel 4 rooms of the same area, respectively, with ventilation. The fragrance retention time of the samples in each room was recorded, the test was repeated three times and the average was taken.
The results are shown in the following table:
sample No. 5 Sample No. 6 Sample 7 Sample 8
Fragrance-lasting time (sky) 16 23 8 9
The result shows that the slow release effect of the essential oil can be improved and the fragrance holding time of the essential oil can be prolonged by matching the slow release fragrance holding particles with the microporous liquid locking layer.
In addition, the cotton sheet of the invention can avoid repeated attack of rhinitis after long-term use.
The specific embodiments described herein are merely illustrative of the spirit of the invention. Various modifications or additions may be made to the described embodiments or alternatives may be employed by those skilled in the art without departing from the spirit of the invention.

Claims (10)

1. The compound aromatic essential oil for resuscitation is characterized in that: the essential oil comprises resuscitation inducing component, soothing component, aroma regulating component, nerve regulating agent and sustained-release aroma-holding particle.
2. The compound aromatic essential oil for resuscitation as claimed in claim 1, wherein: the resuscitation inducing component comprises radix Angelicae Dahuricae essential oil, rhizoma Atractylodis essential oil, rhizoma Acori Graminei essential oil, herba Agastaches essential oil, herba asari essential oil and herba Centipedae essential oil.
3. The compound aromatic essential oil for resuscitation as claimed in claim 1, wherein: the soothing component comprises cinnamon essential oil and wormwood essential oil.
4. The compound aromatic essential oil for resuscitation as claimed in claim 1, wherein: the aroma regulating component comprises clove essential oil.
5. The compound aromatic essential oil for resuscitation as claimed in claim 1, wherein: the nerve regulating agent comprises arbutin, theanine and caffeine.
6. The compound aromatic essential oil for resuscitation as claimed in claim 1, wherein: the slow-release fragrance-holding particles comprise freeze-dried plant composite mineral crystal porous particles.
7. The compound aromatic resuscitation-inducing essential oil as claimed in claim 6, wherein the preparation method of the freeze-dried plant composite mineral crystal porous particles comprises the following steps:
vacuum freeze drying pulverized plant, sieving to obtain plant lyophilized porous particles within 10 μm, mixing pulverized mineral crystal and plant lyophilized porous particles at a weight ratio of 1:1.3-1.8, grinding, and adding binder to obtain lyophilized plant composite mineral crystal porous particles.
8. The compound aromatic resuscitation-inducing essential oil as claimed in any one of claims 1 to 7, wherein: the essential oil consists of 40-50 parts by weight of resuscitation inducing component, 5-10 parts by weight of appeasing component, 0.5-1.5 parts by weight of fragrance regulating component, 0.1-0.5 part by weight of nerve regulating agent and 0.5-1.5 parts by weight of slow-release fragrance-holding particles;
the components for dredging orifices comprise angelica essential oil, rhizoma atractylodis essential oil, rhizoma acori graminei essential oil, patchouli essential oil, asarum essential oil and centipeda minima essential oil in a weight ratio of 3:3:3:1: 2;
the soothing component comprises cinnamon essential oil and wormwood essential oil in a weight ratio of 1: 2;
the aroma regulating component is clove essential oil;
the nerve regulating agent consists of arbutin, theanine and caffeine in a weight ratio of 2.5-3:2-3: 1;
the slow-release aroma-holding particles are freeze-dried plant composite mineral crystal porous particles.
9. A fragrant resuscitation-inducing cotton tablet is characterized in that: comprises a cotton tablet (1) containing the compound aromatic resuscitation-inducing essential oil of any one of claims 1-7.
10. The compound aromatic essential oil for resuscitation as claimed in claim 9, wherein: the cotton piece (1) is composed of a micropore liquid locking layer (2) and breathable cotton layers (3) positioned on two sides of the micropore liquid locking layer (2).
CN202111213239.3A 2021-10-19 2021-10-19 Compound aromatic essential oil and aromatic cotton tablet for dredging orifice Pending CN113797267A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111213239.3A CN113797267A (en) 2021-10-19 2021-10-19 Compound aromatic essential oil and aromatic cotton tablet for dredging orifice

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111213239.3A CN113797267A (en) 2021-10-19 2021-10-19 Compound aromatic essential oil and aromatic cotton tablet for dredging orifice

Publications (1)

Publication Number Publication Date
CN113797267A true CN113797267A (en) 2021-12-17

Family

ID=78897872

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111213239.3A Pending CN113797267A (en) 2021-10-19 2021-10-19 Compound aromatic essential oil and aromatic cotton tablet for dredging orifice

Country Status (1)

Country Link
CN (1) CN113797267A (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102370704A (en) * 2010-08-10 2012-03-14 东源绿保生物科技开发有限公司 Compound camellia seed essential oil
CN108159117A (en) * 2017-12-28 2018-06-15 广西中医药大学第附属医院 A kind of tune lung QI invigorating sachet and preparation method thereof
CN109316473A (en) * 2018-11-30 2019-02-12 合肥中龙神力动物药业有限公司 A kind of water-soluble mono molecule plants essential oil and preparation method thereof
CN111494520A (en) * 2020-06-18 2020-08-07 白振雪 Medicine for treating rhinitis and preparation method and application thereof
CN111838212A (en) * 2020-05-06 2020-10-30 谢允超 Traditional Chinese medicine air disinfection and purification powder for preventing aerosol from spreading
CN112843197A (en) * 2021-03-16 2021-05-28 长春中医药大学附属医院(吉林省中医院) Epidemic prevention nose patch formula extracted from traditional Chinese medicine and preparation process
CN113244296A (en) * 2021-05-19 2021-08-13 中国中医科学院中药研究所 Medicinal volatile oil composition and preparation method and application thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102370704A (en) * 2010-08-10 2012-03-14 东源绿保生物科技开发有限公司 Compound camellia seed essential oil
CN108159117A (en) * 2017-12-28 2018-06-15 广西中医药大学第附属医院 A kind of tune lung QI invigorating sachet and preparation method thereof
CN109316473A (en) * 2018-11-30 2019-02-12 合肥中龙神力动物药业有限公司 A kind of water-soluble mono molecule plants essential oil and preparation method thereof
CN111838212A (en) * 2020-05-06 2020-10-30 谢允超 Traditional Chinese medicine air disinfection and purification powder for preventing aerosol from spreading
CN111494520A (en) * 2020-06-18 2020-08-07 白振雪 Medicine for treating rhinitis and preparation method and application thereof
CN112843197A (en) * 2021-03-16 2021-05-28 长春中医药大学附属医院(吉林省中医院) Epidemic prevention nose patch formula extracted from traditional Chinese medicine and preparation process
CN113244296A (en) * 2021-05-19 2021-08-13 中国中医科学院中药研究所 Medicinal volatile oil composition and preparation method and application thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
朱士顺，等: "被头香囊在鼻科病中的应用", 《中医外治杂志》 *
郭晟，等: "抗感通鼻香囊治疗变应性鼻炎疗效观察", 《广西中医药》 *
高树中: "《中医鼻疗法全书》", 30 September 1994, 华夏出版社 *

Similar Documents

Publication Publication Date Title
CN104305788B (en) A kind of Flos Chrysanthemi Indici mind easing tea health-care medicine pillow and preparation method thereof
CN104295039B (en) Multifunctional building decoration composite board material
CN104292985B (en) A kind of anion lavender fragrance wax crayon
CN105768276A (en) Novel anti-haze mask
CN103520755B (en) A kind of air cleaner material and preparation method thereof
CN105615586A (en) Cortex meliae-containing carpet with function of purifying air
CN111166861A (en) Traditional Chinese medicine particles for treating novel coronavirus pneumonia, preparation method and transdermal patch
CN103875735A (en) Air sterilizing agent and preparation method thereof
CN104966459A (en) Crocus sativus anti-microbial tellurion device for geographical teaching observation and demonstration
CN108159117A (en) A kind of tune lung QI invigorating sachet and preparation method thereof
CN107753631A (en) A kind of Rhinitis treating medicinal cream of antibacterial sterilization and preparation method thereof
CN113797267A (en) Compound aromatic essential oil and aromatic cotton tablet for dredging orifice
CN105250385A (en) Nasal drops for treating infant nasal obstruction
WO2018090345A1 (en) Gel for prevention and treatment of respiratory allergic disease and preparation method thereof
CN111436691A (en) Chinese herbal tea epidemic prevention mask
CN106668602A (en) Medicinal composition formula for treating pharyngitis
CN105998185A (en) Antipyretic gel
CN103989825A (en) Compound anesthetic and preparation method thereof
CN111227366A (en) Anti-virus medicine film mask and preparation method thereof
CN111346128A (en) External plaster for treating infant cold
CN104800508A (en) Mask with function of preventing allergic asthma
CN104957950B (en) Novel desmodium triquetrum anion health care type carpet
CN103202978A (en) Improved traditional Chinese medicinal liniment for treating bromhidrosis
CN104972811A (en) Multifunctional crocus sativus odor type stationery containing box capable of purifying air
CN109432887A (en) A kind of Chinese medicine air filtering core for improving human body constitution, improving immunity

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20211217

RJ01 Rejection of invention patent application after publication